Imaging Findings of Bisphosphonate-Associated Osteonecrosis of the Jaws

BACKGROUND AND PURPOSE: Bisphosphonates are drugs that decrease bone turnover by inhibiting osteoclast activity. An association between the use of bisphosphonates and osteonecrosis of the maxilla and mandible has recently been described. This study describes the imaging findings of bisphosphonate-associated osteonecrosis of the jaws.

MATERIALS AND METHODS: This is a retrospective series of 15 clinically diagnosed patients, identified at 3 centers. Eleven patients were women, of whom 6 had breast cancer, 3 had osteoporosis, and 2 had multiple myeloma. Of the 4 male patients, 2 had prostate cancer, 1 had multiple myeloma, and 1 had osteoporosis. The age range of the patients was 52–85 years (average, 68 years). The mandible was the clinical site of involvement in 11 patients, and the maxilla was involved in 4 patients. Imaging consisted of orthopantomograms in 14 patients, CT scans in 5 patients, and radionuclide bone scan in 1 patient. Nine patients had sequential imaging. Two radiologists reviewed the images.

RESULTS: All of the patients had a degree of osseous sclerosis, most commonly involving the alveolar margin, but lamina dura thickening and full-thickness sclerosis were also observed. The sclerotic change encroached on the mandibular canal in 3 patients. Less commonly encountered findings included poorly healing or nonhealing extraction sockets, periapical lucencies, widening of the periodontal ligament space, osteolysis, sequestra, oroantral fistula, soft tissue thickening, and peristomal new bone formation.

CONCLUSIONS: The most common finding in bisphosphonate-associated osteonecrosis was osseous sclerosis. This varied from subtle thickening of the lamina dura and alveolar crest to attenuated osteopetrosis-like sclerosis.

Bisphosphonates, drugs that decrease bone turnover by inhibiting osteoclast-mediated bone resorption, are used to treat osteoporosis, Paget disease, pain from osseous metastases, and malignancy-related hypercalcemia.1 Recently osteonecrosis of the jaws has been associated with the use of bisphosphonates.2–8 Patients with bisphosphonate-associated osteonecrosis present with nonhealing extraction sockets and painful bone exposure.3,4 Because of the increasing use of bisphosphonates, these complications are now being encountered more frequently. Diagnosis of bisphosphonate-associated osteonecrosis is clinical, because it is preferable to avoid biopsy in patients taking bisphosphonates because of problems with healing postsurgical intervention.9 As a result, radiology is likely to play an increasing role in confirming the diagnosis. This study describes the imaging findings of bisphosphonate-associated osteonecrosis of the jaws.

Materials and Methods
Institutional review board permission was granted for this retrospective study of 15 patients taking bisphosphonates who developed osteonecrosis of the jaws that was diagnosed clinically. Patients included in this study were those currently receiving bisphosphonate therapy who developed painful dental conditions requiring management by an oral and maxillofacial surgeon. This included patients with painful bone exposure, nonhealing extraction sockets, and infection difficult to manage with conventional therapy. The patients were identified at 3 centers. A chart review was performed to document the clinical details. Two radiologists reviewed the imaging of the jaws in consensus, which consisted of orthopantomograms in 14 patients, CT scans in 5 patients, and radionuclide bone scan in 1 patient. Nine patients had sequential imaging.

Eleven patients were women, of whom 6 had breast cancer, 3 had osteoporosis, and 2 had multiple myeloma. Of the 4 male patients, 2 had prostate cancer, 1 had multiple myeloma, and 1 had osteoporosis. The age range of the patients (at the time first seen by oral and maxillofacial surgeon) was 52–85 years (average, 68 years). The mandible was the clinical site of involvement in 11 patients, and the maxilla was involved in 4 patients.

Results
Clinical data from the 15 patients are shown in Table 1. Diagrams of normal orthopantomogram appearance and mild and advanced bisphosphonate-associated osteonecrosis are shown in Fig 1A–C. All of the patients in our study (15 patients) had a degree of osseous sclerosis, most commonly involving the alveolar margin (10 patients; Fig 2), but lamina dura thickening (7 patients) and full-thickness sclerosis (6 patients) were also observed (Figs 3 and 4). The sclerotic change encroached on the mandibular (inferior alveolar) canal in 3 patients. Five patients had poorly healing or nonhealing extraction sockets and periapical lucencies. Four patients had widening of the periodontal ligament space and osteolysis (Fig 5), 3 patients had sequestra (Fig 6), and 2 patients had oroantral fistula. Single patients had soft tissue thickening and periosteal new bone formation. The frequency of radiographic findings is shown in Table 2. The single patient in our series...
| Patient | Age, years | Sex | Underlying Condition | Presentation | Location | Bisphosphonate | Biopsy | Management |
|---------|------------|-----|----------------------|--------------|----------|---------------|--------|------------|
| 1       | 65         | F   | Multiple myeloma     | Nonhealing extraction socket/necrotic bone | Left maxilla | Zoledronate   | Necrotic bone | Curettage, antibiotics, hyperbaric oxygen therapy |
| 2       | 67         | F   | Metastatic breast cancer | Pain; nonhealing extraction socket | Right posterior mandible | Pamidronate changed to zoledronate | Not done | Analgesia; antibiotics |
| 3       | 60         | F   | Metastatic breast cancer | Nonhealing extraction site; later complicated by infection and fistula formation | Left posterior mandible, third molar | Pamidronate | Chronic osteomyelitis | Curettage; antibiotic therapy |
| 4       | 77         | F   | Multiple myeloma      | Multifocal exposed bone | Bilateral body and symphysis of mandible | Pamidronate changed to zoledronate | Osteonecrosis, extensive bacterial and inflammatory cell infiltration (Fig 5C) | Mouth wash, antibiotics, surgical debridement |
| 5       | 64         | M   | Multiple myeloma      | Chronic nasal infection/sinusitis; pain | Central maxilla | Clodronate and pamidronate in the past | Not done | Long-term antibiotics |
| 6       | 61         | M   | Metastatic prostate cancer | Painful bone exposure; subsequent loosening of teeth and spontaneous sequestration of the left mandible | Bilateral mandibular bodies | Zoledronate | Not done | Mouth rinses, antibiotics; filing of sharp bone spicule; removal of sequestra; extraction of tooth |
| 7       | 75         | F   | Metastatic breast cancer | Infection, subcutaneous fistula; painful bone exposure | Initially anterior mandible, subsequently bilateral mandibular bodies | Zoledronate | Active osteomyelitis | IV antibiotics, then oral; marginal mandibulectomy |
| 8       | 52         | F   | Metastatic breast cancer | Nonhealing extraction socket; painful bone exposure | First left mandibular molar | Zoledronate | Sequestrum and chronically inflamed mucosa | Mouth rinses; antibiotics; analgesia; debridement of extraction site |
| 9       | 79         | M   | Metastatic prostate cancer | Infection; pain | Right posterior mandible | Alendronate changed to an injectable bisphosphonate | Not done | Antibiotics; mouth rinses |
| 10      | 54         | F   | Metastatic breast cancer | Pain | Anterior mandible | Zoledronate | Not done | None |
| 11      | 82         | F   | Osteoporosis          | Nonhealing extraction socket | Left maxilla | Alendronate | Necrotic bone coated with bacterial colonies | Antibiotics, debridement |
| 12      | 70         | F   | Osteoporosis          | Nonhealing extraction socket | Right posterior mandible | Alendronate | Not done | Curettage, antibiotics |
| 13      | 85         | F   | Osteoporosis          | Nonhealing extraction socket; infection | Left posterior mandible | Alendronate | Necrotic bone coated with bacteria | Curettage, antibiotics |
| 14      | 74         | M   | Osteoporosis          | Infected exposed bone; pain | Right posterior body of mandible | Alendronate | Not done | Antibiotics; mouth washes, incision and drainage |
| 15      | 54         | F   | Metastatic breast cancer | Pain, swelling, exposed bone, loose teeth; palatonasal and palatocanal fistula, sinusitis | Maxilla, bilateral | Zoledronate, alendronate, and pamidronate in the past | Osteonecrosis and acute osteomyelitis, abundant bacteria associated with bone infiltration | Multiple dental extractions, bilateral subtotal maxillectomy; antibiotics |

**Note:**—M indicates male; F, female.
who had technetium Tc99m hydroxymethylene diphosphonate (Tc99m-HDP) bone scan imaging had 2 examinations separated by 3 years and demonstrated progressively increased radiotracer uptake around the extraction socket in the right posterior mandible.

Discussion

Normal bone is a dynamic organ with a balance between bone formation from osteoblasts and resorption via osteoclasts. Bisphosphonates are drugs that decrease bone resorption by inhibition of osteoclasts. First-generation bisphosphonates, such as clodronate and etidronate, are oral agents and act by causing osteoclast death by inducing apoptosis. The newer nitrogen-containing bisphosphonates include alendronate, risedronate, and the intravenously administered pamidronate and zoledronate. These have a higher potency and inhibit osteoclasts by targeting an enzyme in the cholesterol biosynthetic pathway called farnesyl diphosphate synthase.

Bisphosphonate-associated osteonecrosis of the jaws is a newly recognized entity, and formal diagnostic criteria have yet to be defined. The diagnosis of this entity relies on a characteristic clinical presentation of painful bone exposure (Fig 7), histologic evidence of osteonecrosis (defined as empty lacunae and calcified matrix/osteopetrotic change with or without bacterial invasion), the absence of any histologic evidence of neoplasm, and a history of use of bisphosphonates. However, the rigid application of these criteria poses a number of problems. First, cases of exposed bone are not always associated with pain. In addition, histologic confirmation of the diagnosis is not always possible, as a biopsy is often avoided because these patients have problems with healing. Hence, biopsy is recommended only when there is high clinical suspicion of metastasis. The diagnosis of osteonecrosis is, therefore, largely based on clinical criteria, with the key elements being an appropriate clinical presentation and bisphosphonate use. It should be noted that because the skeletal half-life of bisphosphonates is more than 10 years, it is possible that complications may occur after cessation of therapy.

The exact mechanism by which bisphosphonates cause osteonecrosis of the jaws is unclear. Most of the current theories are extrapolated from the known mechanisms of action of bisphosphonates and cases of osteonecrosis of the jaws that have occurred in association with bisphosphonate use. The metabolic theory is based on an altered balance between the actions of osteoclasts and osteoblasts. In support of this theory is the report of a child treated with bisphosphonates, albeit at a greater-than-recommended dose, that led to a generalized osteoporosis-like state. In addition, the clinical effect of osteoporosis on the jaws is similar to that of bisphosphonates, with osteoporotic patients prone to problems with healing and infection of the jaws after dental procedures.

The antivascular theory is based on the known antiangiogenic effects of bisphosphonates that have been documented both in vitro and in vivo. Against this theory is the finding that more potent antiangiogenic drugs do not cause osteonecrosis of the jaws and the presence of normal numbers of
blood vessels in histologic sections of bisphosphonate-associated osteonecrosis.13

The Wolf law19 states that bone remodeling occurs secondary to the forces applied to it. Because the mandible and maxilla are subject to strong occlusal forces transmitted by the teeth and periodontal ligaments, there is a high bone turnover, which predisposes the jaws to certain conditions. “Phossy jaw”13,20 is a condition historically described in match factory workers in the mid-1800s who were exposed to metabolically active white phosphorus. This resulted in a painful and disfiguring condition of the jaws, with superimposed infection leading to a 20% mortality rate in this preantibiotic era.21 The accumulation of phosphorous in the jaws in this condition was thought related to the high bone turnover. Likewise, as bisphosphonates inhibit osteoclasts, they decrease bone remodeling and predispose bone to accumulated microdamage,22 again with the jaws particularly susceptible due to the high bone turnover. Supporting this theory is that there has been only 1 case of bisphosphonate-associated osteonecrosis outside the oral cavity.23

The most commonly encountered radiographic finding in our series was osseous sclerosis, which was present in all 15 of the patients to a variable extent. The normal radiographic appearance of the alveolar crest is of a sharply defined thin radiodense line that is continuous with the lamina dura around the root of the tooth, also a thin, well-defined line. The 1- to 2-mm lucency between the root of the tooth and the lamina dura corresponds with the space for the periodontal ligament.24 In our series, case subjects with mild involvement had sclerosis of the alveolar margin and thickening of the lamina dura. The changes were often diffuse rather than localized to the area of clinical involvement. More advanced case subjects had greater degrees of osseous sclerosis, which may be attenuated and reminiscent of osteopetrosis and may narrow the mandibular canal. In the case subjects with sequential imaging, the sclerotic changes were often progressive. The generalized nature of the sclerotic changes in the jaws in bisphosphonate-associated osteonecrosis helps to differentiate this entity from reactive sclerosis, which tends to be localized around inflammatory foci.

The less frequently encountered findings in our series, such as osteolysis, soft tissue swelling, periosteal new bone formation, periapical lucencies, ooronal fistula, and sequestra, are likely to correspond with the presence of infection. In our series, 7 of 8 patients who had histopathologic assessment of their disease had changes of osteomyelitis. Although the histopathology of these patients demonstrates osteomyelitis, it is important to note that the oral cavity offers a unique microbial environment in which exposed bone is immediately contaminated with oral flora. Thus, bacterial colonies, as well as in-

![Image of radiographic findings](image-url)
Inflammatory infiltrates, are ubiquitous in oral necrotic bone such that differentiation between osteonecrosis and osteomyelitis can be muddied by this peculiarity. Our findings suggest that the radiographic appearance of bisphosphonate-associated osteonecrosis is in part determined by the presence of superimposed infection. This may prove to be a useful form of radiologic classification and correlates with a staging system proposed by Ruggiero. To our knowledge, there is little in the literature regarding imaging findings in bisphosphonate-associated osteonecrosis. Most authors describe lytic destructive changes, sequestra, and soft tissue swelling, though Marx et al refer to the entity as “bisphosphonate associated osteopetrosis,” making reference to sclerotic changes in the jaws.

The radiologic differential diagnosis for bisphosphonate-associated osteonecrosis includes chronic sclerosing osteomyelitis of the jaws, osteoradionecrosis, metastasis, and Paget disease. Chronic sclerosing osteomyelitis of the mandible has the radiologic hallmarks of periosteal new bone, sclerosis, osseous expansion, and sequestra (Fig 8). Osteoradionecrosis occurs after radiation therapy to the oral cavity and is radiologically manifested by poorly defined destruction of the mandible (Fig 9). Metastases to the jaws are uncommon and are most commonly found in the posterior reaches of the mandible. They are most frequently lytic lesions, with exceptions being prostate and breast cancer metastases, which may be sclerotic (Fig 10). Paget disease is typically manifest by osseous expansion and coarsened trabeculae.

The main limitation of our study is the small number of patients. Larger numbers are required before generalizations can be made regarding the typical radiologic findings in bisphosphonate-associated osteonecrosis. Another limitation in our study is the variability in imaging studies between patients, which makes it difficult to analyze the frequency of findings. CT is a more sensitive imaging technique compared with panoramic radiography; subsequently, findings such as soft tissue swelling, periosteal new bone, and sequestrum are easier to detect on CT and may not be seen on orthopantomography. Finally, because the clinical details were obtained from a chart review, some details, such as the length of time that subjects were treated with bisphosphonates, were not available.
Conclusions
In our study, the most common finding in bisphosphonate-associated osteonecrosis was osseous sclerosis. This varied from subtle thickening of the lamina dura and alveolar crest to attenuated osteopetrosis-like sclerosis. It is important for radiologists to recognize this entity, because imaging is likely to play an increasing role in confirming the diagnosis, as there is a preference to avoid biopsy.

Acknowledgments
We acknowledge Drs. Robin Cassumbhoy and Bernard Lim for contributing patients to the series, Dr. Jeffery Stewart for the provision of histologic sections, and Scott Jeffs for medical illustration.

Table 2: Frequency of radiographic findings

| Radiographic Finding                  | No. of Cases |
|--------------------------------------|--------------|
| Osseous sclerosis (any type)         | 15           |
| Alveolar margin                      | 10           |
| Lamina dura thickening               | 7            |
| Full thickness of bone               | 6            |
| Periapical lucency                   | 5            |
| Poorly healing extraction socket     | 5            |
| Osteolysis                           | 4            |
| Widened periodontal ligament space   | 4            |
| Encroachment on the mandibular canal | 3            |
| Sequestrum                           | 3            |
| Oroantral fistula                    | 2            |
| Periosteal new bone                  | 1            |
| Soft tissue swelling                 | 1            |
References

1. Sparidans RW, Twiss IM, Talbot S. Bisphosphonates in bone diseases. Pharm World Sci 1998;20:206–13
2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115–17
3. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527–34
4. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567–75
5. Migliorati CA, Schubert MM, Peterson DE, et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005;104:83–93
6. Bagan JV, Murillo J, Jimenez Y, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005;34:120–23
7. Carneiro E, Vibhute P, Montazer A, et al. Bisphosphonate-associated mandibular osteonecrosis. AJNR Am J Neuroradiol 2006;27:1096–97
8. Kolata G. Drug for bones is linked to jaw disease. New York Times June 2, 2006;sect A:1
9. Novartis. Expert Panel Recommendation for the Prevention, Diagnosis and Treatment of Osteonecrosis of the Jaw. East Hanover, NJ: Novartis; 2005. Available at: http://www.ida.org/DFHMS/DODICKET/AC/05/briefing/2005-409582_02_11-Novartis-Zometa-App-11.pdf
10. Tolar J, Teitelbaum SL, Orchard PJ. Osteopetrosis. N Engl J Med 2004;351:2839–49
11. Reszka AA, Rodan GA. Mechanism of action of bisphosphonates. Curr Osteoporos Rep 2003;1:45–52
12. Reszka AA, Rodan GA. Nitrogen-containing bisphosphonate mechanism of action. Mini Rev Med Chem 2004;4:711–19
13. Hellstein JW, Marek CL. Bisphosphonate osteochonemecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005;63:682–89
14. Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003;349:457–63
15. Junquera L, Rodriguez-Recoio C, Villarreal P, et al. Autosomal dominant osteopetrosis and maxillomandibular osteomyelitis. Am J Otolaryngol 2005;26:275–78
16. Batra P, Shah N. Recalcitrant osteomyelitis following tooth extraction in a case of malignant osteopetrosis. Int Dent J 2004;54:418–23
17. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055–61
18. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538–44
19. Messe AM, Willey JS, Bateman TA. Potential role of proinflammatory cytokines in nerve damage related bone loss. Biomed Sci Instrum 2004;40:266–71
20. Donoghue AM. Bisphosphonates and osteonecrosis: analogy to phossy jaw. Med J Aust 2005;183:163–64
21. Miles AE. Phosphorus necrosis of the jaw: ‘phossy jaw’. Br Dent J 1972;133:203–06
22. Seeman E, Delmas PD. Bone quality—the material and structural basis of bone strength and fragility. N Engl J Med 2006;354:2250–61
23. Polizotto MN, Cousini V, Schwarzer AP. Bisphosphonate-associated osteonecrosis of the auditory canal. Br J Haematol 2006;132:114
24. White S, Pharrmah M. Oral Radiology, Principles and Interpretation, 4th ed. St. Louis: Mosby; 2000
25. Ruggiero SL. Bisphosphonate-induced osteonecrosis: OMS perspective. Paper presented at: Meeting of the American Association of Oral Maxillofacial Surgeons, 2005; Boston, September 20–25, 2005
26. Chiandussi S, Biasotto M, Dore F, et al. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac Radiol 2006;35:236–43
27. Hino S, Murase R, Terakado N, et al. Response of diffuse sclerosing osteomyelitis of the mandible to alendronate: follow-up study by 99mTc scintigraphy. Int J Oral Maxillofac Surg 2005;34:576–78
28. Orpe EC, Lee L, Pharrmah M. A radiological analysis of chronic sclerosing osteomyelitis of the mandible. Dentomaxillofac Radiol 1996;25:25–29
29. Resnick D, Kransdorf M. Bone and Joint Imaging, 3rd ed. Philadelphia: Elsevier Saunders; 2005
30. van der Waal RI, Buter J, van der Waal I. Oral metastases: report of 24 cases. Br J Oral Maxillofac Surg 2003;41:3–6

AJNR Am J Neuroradiol 28:1139–45 | Jun-Jul 2007 | www.ajnr.org 1145